Table 2 Multivariable analysis for cumulative incidence of relapse, relapse free survival and overall survival according to NGS MRD status.

From: Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study

 

CIR

RFS

OS

HR

CI

P-value

HR

CI

P-value

HR

CI

P-value

NGS-MRD (neg)

1

  

1

  

1

  

NGS MRD (DTA)

1.77

0.86–3.64

0.12

1.79

0.97–3.30

0.062

2.16

1.07–4.37

0.032

NGS MRD (other)

2.73

1.48–5.03

0.0013

2.23

1.31–3.81

0.0033

2.26

1.21–4.24

0.011

ELN2017 (FAV)

1

  

1

  

1

  

ELN2017 (INT)

1.78

0.90–3.53

0.10

1.63

0.89–2.97

0.11

1.70

0.80–3.59

0.17

ELN2017 (ADV)

1.62

0.78–3.35

0.19

1.77

0.95–3.31

0.074

2.64

1.25–5.56

0.011

Age

1.01

0.99–1.04

0.33

1.01

0.99–1.04

0.46

1.01

0.99–1.04

0.33

  1. NS not significant, HR Hazard ratio, CI 95% confidence interval, FAV favorable, INT intermediate, ADV adverse, CIR cumulative incidence of relapse, RFS relapse-free survival, OS overall survival.
Back to article page